RBPJL

Summary

RBPJL (recombination signal binding protein for immunoglobulin kappa J region like, HGNC:13761) is a protein-coding gene on chromosome 20q13.12, encoding Recombining binding protein suppressor of hairless-like protein (Q9UBG7). Putative transcription factor, which cooperates with EBNA2 to activate transcription.

This gene encodes a member of the suppressor of hairless protein family. A similar protein in mouse is a transcription factor that binds to DNA sequences almost identical to that bound by the Notch receptor signaling pathway transcription factor recombining binding protein J. The mouse protein has been shown to activate transcription in concert with Epstein-Barr virus nuclear antigen-2. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 11317 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 88 total — 1 pathogenic
• MANE Select transcript: NM_014276

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13761
Approved symbol	RBPJL
Name	recombination signal binding protein for immunoglobulin kappa J region like
Location	20q13.12
Locus type	gene with protein product
Status	Approved
Aliases	RBP-L, SUH, SUHL
Ensembl gene	ENSG00000124232
Ensembl biotype	protein_coding
OMIM	616104
Entrez	11317

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000343694, ENST00000372741, ENST00000372743, ENST00000464504, ENST00000622729

RefSeq mRNA: 3 — MANE Select: NM_014276 NM_001281448, NM_001281449, NM_014276

CCDS: CCDS13349, CCDS63283, CCDS63284

Canonical transcript exons

ENST00000343694 — 12 exons

Exon	Start	End
ENSE00000844949	45309567	45309692
ENSE00000844951	45311589	45311659
ENSE00000844952	45311839	45311954
ENSE00000844954	45312221	45312395
ENSE00000844956	45313468	45313605
ENSE00000844962	45316187	45316342
ENSE00001304769	45308143	45308251
ENSE00001750836	45316686	45317824
ENSE00003601292	45316477	45316580
ENSE00003725911	45314413	45314565
ENSE00003741821	45314035	45314144
ENSE00003844778	45306840	45306944

Expression profiles

Bgee: expression breadth ubiquitous, 122 present calls, max score 99.56.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.7613 / max 781.6711, expressed in 7 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
184881	0.7613	7

Top tissues by expression

267 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.56	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.29	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.39	gold quality
pancreas	UBERON:0001264	81.73	gold quality
body of stomach	UBERON:0001161	69.19	gold quality
stomach	UBERON:0000945	63.87	gold quality
fundus of stomach	UBERON:0001160	57.40	gold quality
tibialis anterior	UBERON:0001385	55.63	silver quality
triceps brachii	UBERON:0001509	54.30	gold quality
left ventricle myocardium	UBERON:0006566	51.50	gold quality
Brodmann (1909) area 46	UBERON:0006483	51.15	gold quality
islet of Langerhans	UBERON:0000006	50.74	gold quality
quadriceps femoris	UBERON:0001377	50.00	gold quality
deltoid	UBERON:0001476	49.90	gold quality
ileal mucosa	UBERON:0000331	49.63	silver quality
vastus lateralis	UBERON:0001379	49.45	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
epithelial cell of pancreas	CL:0000083	49.18	gold quality
hair follicle	UBERON:0002073	49.18	gold quality
myocardium	UBERON:0002349	49.17	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
buccal mucosa cell	CL:0002336	48.85	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
nasal cavity epithelium	UBERON:0005384	48.72	gold quality
oviduct epithelium	UBERON:0004804	48.66	gold quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality
cervix epithelium	UBERON:0004801	48.41	gold quality
pancreatic ductal cell	CL:0002079	48.38	silver quality
lateral globus pallidus	UBERON:0002476	48.37	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	30.10
E-GEOD-81547	yes	25.20

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
KAT2B
PTF1A

Upstream regulators (CollecTRI, top): RBPJ

miRNA regulators (miRDB)

28 targeting RBPJL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-3160-3P	99.07	64.78	955
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-4764-5P	98.88	65.53	894
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-6754-5P	98.60	65.54	1627
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-6818-5P	97.50	67.10	1167
HSA-MIR-5699-5P	97.36	67.03	1014
HSA-MIR-3116	97.07	65.78	1324
HSA-MIR-759	96.16	66.77	873
HSA-MIR-5191	95.22	64.69	354
HSA-MIR-4508	90.37	59.62	240

Literature-anchored findings (GeneRIF, showing 3)

• P48 interacts with the RBP-L and RBP-J subunits primarily through two short conserved tryptophan-containing motifs, similar to the motif of the Notch intracellular domain (NotchIC) that interacts with RBP-J. (PMID:16354684)
• Amerindian-derived population-specific Thr280Met variant may modify risk of diabetes mellitus by regulating exocrine enzyme expression. (PMID:29302047)
• In mouse, there is cooperative transcriptional activity of RBP-L with EBNA-2. (PMID:9111338)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	rbpjl	ENSDARG00000074148
mus_musculus	Rbpjl	ENSMUSG00000017007
rattus_norvegicus	Rbpjl	ENSRNOG00000026295
caenorhabditis_elegans		WBGENE00002245

Paralogs (1): RBPJ (ENSG00000168214)

Protein

Protein identifiers

Recombining binding protein suppressor of hairless-like protein — Q9UBG7 (reviewed: Q9UBG7)

Alternative names: Transcription factor RBP-L

All UniProt accessions (3): A0A087X185, Q9UBG7, Q5QPV1

UniProt curated annotations — full annotation on UniProt →

Function. Putative transcription factor, which cooperates with EBNA2 to activate transcription.

Subunit / interactions. Interacts weakly with EBNA2. Does not interact with any Notch proteins.

Subcellular location. Nucleus.

Similarity. Belongs to the Su(H) family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UBG7-1	1	yes
Q9UBG7-2	2

RefSeq proteins (3): NP_001268377, NP_001268378, NP_055091* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR014756	Ig_E-set	Homologous_superfamily
IPR015350	Beta-trefoil_DNA-bd_dom	Domain
IPR015351	RBP-J/Cbf11/Cbf12_DNA-bd	Domain
IPR036358	BTD_sf	Homologous_superfamily
IPR037095	RBP-J/Cbf11_DNA-bd_sf	Homologous_superfamily
IPR038007	RBP-Jkappa_IPT	Domain
IPR040159	CLS_fam	Family

Pfam: PF09270, PF09271, PF20144

UniProt features (9 total): region of interest 4, chain 1, domain 1, compositionally biased region 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBG7-F1	80.58	0.54

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 66 (showing top): XU_GH1_AUTOCRINE_TARGETS_UP, GROSS_HYPOXIA_VIA_HIF1A_DN, DBP_Q6, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, SHEN_SMARCA2_TARGETS_DN, GOMF_CHROMATIN_BINDING, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP, MIKKELSEN_MEF_HCP_WITH_H3K27ME3, FEVR_CTNNB1_TARGETS_UP, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOMF_DNA_BINDING_TRANSCRIPTION_ACTIVATOR_ACTIVITY, PRC1_BMI_UP.V1_DN

GO Biological Process (5): signal transduction (GO:0007165), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (8): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), transcription regulator complex (GO:0005667)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
DNA-templated transcription	2
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
binding	2
transcription cis-regulatory region binding	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transcription regulator activity	1
nucleic acid binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

1304 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RBPJL	PTF1A	Q7RTS3	992
RBPJL	MAML1	Q92585	758
RBPJL	DLL4	Q9NR61	645
RBPJL	MAML2	Q8IZL2	601
RBPJL	CPA1	P15085	589
RBPJL	TCF12	Q99081	577
RBPJL	HNF1A	P20823	539
RBPJL	CPA2	P48052	528
RBPJL	NR5A2	O00482	522
RBPJL	BHLHA15	Q7RTS1	511
RBPJL	MAML3	Q96JK9	477
RBPJL	FLT4	P35916	473
RBPJL	PIP4K2A	P48426	428
RBPJL	JAG1	P78504	405
RBPJL	HEY1	Q9Y5J3	400

IntAct

6 interactions, top by confidence:

A	B	Type	Score
MEOX2	RBPJL	psi-mi:“MI:0915”(physical association)	0.560
RBPJL	Kdm1a	psi-mi:“MI:0915”(physical association)	0.400
RBPJL	PCDH7	psi-mi:“MI:0914”(association)	0.350
RBPJL	MEOX2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): RBPJL (Affinity Capture-Western), RBPJL (Two-hybrid), CELSR2 (Affinity Capture-MS), DNAJB5 (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), BORA (Affinity Capture-MS), FAT3 (Affinity Capture-MS), PCDH7 (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A0AVI4, A0JMH2, A2ARP1, B0BNK8, F7E7M3, O00562, O08674, O35954, P0C644, P10588, P17105, P23677, Q08DJ7, Q08DK0, Q15173, Q28647, Q29RH2, Q4R7D0, Q4R8X4, Q5R5N9, Q5SSF7, Q5U2N3, Q5VWP2, Q5XIL6, Q5XIV0, Q5ZL95, Q6PD28, Q6PFW1, Q7ZUP1, Q80W83, Q80YU0, Q86TL0, Q8C152, Q8K304, Q8N159, Q8NEK8, Q8R071, Q8R307, Q8R4H7, Q8VDR9

Diamond homologs: O02019, O08674, O76808, P28159, P31266, Q06330, Q3SZ41, Q5RFK6, Q91880, Q9UBG7, V6CLJ5, O74954, Q9Y1T5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

88 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	69
Likely benign	1
Benign	14

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1330181	GRCh37/hg19 20q13.12-13.13(chr20:42985044-48599046)x1	Pathogenic

SpliceAI

2275 predictions. Top by Δscore:

Variant	Effect	Δscore
20:45309690:GCG:G	donor_gain	1.0000
20:45311953:GG:G	donor_gain	1.0000
20:45311954:GG:G	donor_gain	1.0000
20:45312392:GATC:G	donor_gain	1.0000
20:45312393:ATC:A	donor_gain	1.0000
20:45312394:TC:T	donor_gain	1.0000
20:45312396:G:GG	donor_gain	1.0000
20:45312404:G:GT	donor_gain	1.0000
20:45314151:G:GT	donor_gain	1.0000
20:45314155:G:GT	donor_gain	1.0000
20:45314156:G:T	donor_gain	1.0000
20:45316338:TAGAG:T	donor_loss	1.0000
20:45316341:AG:A	donor_loss	1.0000
20:45316342:GGTGA:G	donor_loss	1.0000
20:45316343:GTGA:G	donor_loss	1.0000
20:45316474:CA:C	acceptor_loss	1.0000
20:45316475:A:AG	acceptor_gain	1.0000
20:45316475:AGC:A	acceptor_loss	1.0000
20:45316476:G:A	acceptor_loss	1.0000
20:45316476:G:GG	acceptor_gain	1.0000
20:45316476:GC:G	acceptor_gain	1.0000
20:45316476:GCT:G	acceptor_gain	1.0000
20:45316476:GCTGA:G	acceptor_gain	1.0000
20:45306941:GCAG:G	donor_gain	0.9900
20:45306943:AGGT:A	donor_loss	0.9900
20:45306944:GGT:G	donor_loss	0.9900
20:45306945:G:GC	donor_loss	0.9900
20:45306946:T:G	donor_loss	0.9900
20:45307452:TGG:T	donor_gain	0.9900
20:45307454:G:GT	donor_gain	0.9900

AlphaMissense

3345 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:45309665:C:A	A77D	1.000
20:45309669:G:C	Q78H	1.000
20:45309669:G:T	Q78H	1.000
20:45309670:A:G	K79E	1.000
20:45309671:A:T	K79I	1.000
20:45309672:A:C	K79N	1.000
20:45309672:A:T	K79N	1.000
20:45312356:A:G	K194E	1.000
20:45312358:G:C	K194N	1.000
20:45312358:G:T	K194N	1.000
20:45313500:T:C	F218L	1.000
20:45313502:C:A	F218L	1.000
20:45313502:C:G	F218L	1.000
20:45313506:C:A	R220S	1.000
20:45313536:T:G	Y230D	1.000
20:45313581:T:A	W245R	1.000
20:45313581:T:C	W245R	1.000
20:45316241:T:A	W359R	1.000
20:45316241:T:C	W359R	1.000
20:45309656:C:A	A74D	0.999
20:45309670:A:C	K79Q	0.999
20:45309671:A:C	K79T	0.999
20:45309673:T:C	S80P	0.999
20:45309674:C:T	S80L	0.999
20:45309676:T:C	Y81H	0.999
20:45309680:G:A	G82E	0.999
20:45309686:A:T	E84V	0.999
20:45311590:T:C	F87L	0.999
20:45311592:C:A	F87L	0.999
20:45311592:C:G	F87L	0.999

dbSNP variants (sampled 300 via entrez): RS1000519809 (20:45317741 C>A,T), RS1000751678 (20:45307612 T>A), RS1001417372 (20:45313410 C>G), RS1001471688 (20:45312835 A>G), RS1001565081 (20:45313134 T>A), RS1003569997 (20:45315801 A>G), RS1003985619 (20:45317815 T>A,C), RS1004770218 (20:45310335 G>A), RS1004924489 (20:45306924 T>A), RS1005313170 (20:45305195 G>A), RS1005582282 (20:45312718 G>A), RS1005590936 (20:45309773 T>G), RS1005673969 (20:45305564 A>T), RS1005787880 (20:45315288 C>T), RS1005928283 (20:45308314 C>A)

Disease associations

OMIM: gene MIM:616104 | disease phenotypes: MIM:616056, MIM:125853

GenCC curated gene-disease

Mondo (2): developmental and epileptic encephalopathy, 26 (MONDO:0014477), type 2 diabetes mellitus (MONDO:0005148)

Orphanet (1): Non-specific early-onset epileptic encephalopathy (Orphanet:442835)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010725_40	Malaria	1.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003924	Diabetes Mellitus, Type 2	C18.452.394.750.149; C19.246.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
aristolochic acid I	increases expression	1
sodium arsenite	increases expression	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00006163	PHASE4	COMPLETED	Computer-assisted Diabetes Self-management Interventions
NCT00036504	PHASE4	COMPLETED	Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
NCT00044460	PHASE4	COMPLETED	Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00095446	PHASE4	COMPLETED	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00101751	PHASE4	COMPLETED	INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00110370	PHASE4	COMPLETED	Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00118950	PHASE4	COMPLETED	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118963	PHASE4	COMPLETED	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
NCT00121966	PHASE4	COMPLETED	South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
NCT00123604	PHASE4	COMPLETED	Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes
NCT00123643	PHASE4	COMPLETED	Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
NCT00124397	PHASE4	COMPLETED	Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00129233	PHASE4	COMPLETED	Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance
NCT00133718	PHASE4	COMPLETED	A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
NCT00135070	PHASE4	TERMINATED	Hospital In-Patient Insulin Study
NCT00141232	PHASE4	COMPLETED	Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00144144	PHASE4	UNKNOWN	A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes
NCT00149331	PHASE4	COMPLETED	The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy
NCT00162357	PHASE4	COMPLETED	Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty
NCT00174681	PHASE4	COMPLETED	Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
NCT00174824	PHASE4	COMPLETED	Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
NCT00177398	PHASE4	COMPLETED	Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
NCT00179400	PHASE4	COMPLETED	The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans
NCT00184561	PHASE4	COMPLETED	Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184626	PHASE4	COMPLETED	Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00191178	PHASE4	COMPLETED	Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
NCT00191282	PHASE4	COMPLETED	Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191464	PHASE4	COMPLETED	Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
NCT00192803	PHASE4	UNKNOWN	Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
NCT00202033	PHASE4	COMPLETED	Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes
NCT00205660	PHASE4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00212290	PHASE4	COMPLETED	Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212303	PHASE4	COMPLETED	Exercise Training in Type 2 Diabetes and Hypertension
NCT00225342	PHASE4	WITHDRAWN	Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
NCT00238472	PHASE4	COMPLETED	A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
NCT00239538	PHASE4	COMPLETED	SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
NCT00240253	PHASE4	COMPLETED	A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
NCT00240422	PHASE4	COMPLETED	Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
NCT00241085	PHASE4	COMPLETED	Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus